

Who We are



We are a vibrant science and technology company







our ideas are everywhere

from cancer therapies and laboratory tools to the display of your smartphone or the effect pigment coating of your car.

To us, it's about discovering and developing for life in all its vibrancy, drawing our unique expertise in health care, life science and performance materials.

CuRious mInds dedicated to human progress

Our global network of scientists, experts and thought leaders is driven by the passion to explore and the prospect of making a meaningful difference in the world.







AGRCK

Every day, our nearly 52,000 employees work in 66 countries to make a positive difference to millions of people's lives by creating more joyful and sustainable ways to live.

Darmstadt, Germany







We are known as Merck internationally except for the United States and Canada, where we operate as EMD Serono in the biopharmaceutical business, MilliporeSigma in the life science business, and EMD Performance Materials in the high-tech materials business.



Successful business with a

Conscience

We take responsibility for our products, the environment and the people around us – especially our employees and the communities in which we operate. In doing so, safety and ethical aspects matter just as much to us as business success.





MeRck's Global Responsibility

Corporate Responsibility

We identify and initiate opportunities to create shared value across Merck.

We collaborate in addressing major global challenges by delivering solutions that enable

- economic
- social
- environmental

value within and beyond business operations.

Global Health

We improve health of underserved populations in low- and middle-income countries

- through Merck's innovations in science & technology
- in close collaboration with our external partners

Our overarching principle is **shared value**:


we identify societal and environmental needs that we can service with our assets in a win-win approach for society and Merck.




Global Health at

MERCK

We improve the health of underserved populations in low- and middle-income countries through Merck's science & technology innovation, and in close collaboration with our external partners.



Shared value, schistosomiasis and malaria are our priority areas



¹ Defined as elimination of schistosomiasis as a public health problem

Our principle: Shared value





Innovative solutions that address unmet GH needs:

We develop new integrated drug, diagnostic, and vector control solutions for the infectious disease space, and we take a leading role in the elimination of schistosomiasis



Cross-sector partners to amplify impact:

We participate in multi-stakeholder GH platforms and the ATM Index to help shape the agenda and progress of the SDGs and catalyze access alliances for our solutions



Business opportunities to serve unmet needs sustainably:

We help Merck's business to improve the health of the underserved in a sustainable way by providing access to Merck's portfolio across the 3 Merck business sectors



Using

Shared value

to improve the health of underserved populations



Our guiding principle is shared value

Social value shared value Business value

We identify societal and environmental needs that we can service with our assets in a win-win approach for society and Merck

GH Committed to the UN SDGs Leaving No One Behind

17 + 169 + 230 + Indicators goals

Objectives

- Building on the success of the Millennium Development Goals
- Ensuring sustainable social and economic progress worldwide
- Integrating and balancing economic, social and environmental dimensions
- Ambitious agenda for all 7 billion of the world's people, not just the poorest
- New models of partnership

Advancing Sustainable Development Goals a business opportunity to seize

































Better Business, Better World, The report of the Business & Sustainable Development Commission, January 2017

GH main contribution into UN SDGs






































Leaving no one behind

Universal Health Coverage (UHC)

- "Universal health coverage is both a SDG goal in itself and a means for implementing other goals."
- implementation of public health interventions, disease prevention and health promotion
- Global UHC movement due to: 1) importance of access to health; 2) importance of health in the economy; 3) growing burden of NCDs.

SDG 3.8

"Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all."



The Global Health Leaders, Goals, **Drivers**

Develop innovative products in the fight against malaria and infectious diseases

Global Health

Manfred **Klevesath**



Create new shared value opportunities, health system strengthening



and capacitybuilding throughout the value chain

Access to Health

Frédérique Santerre

Merck Schisto

Eliminate schistosomiasis as a public health burden

> Global Schisto Alliance

Merck as a trusted, responsible and equal partner in **GH** for our stakeholders

Merck Global Health Institute

A healthier future for all:

individuals,

communities,

countries

Jutta Reinhard-Rupp

Our team members as motivated, inspired and responsible citizens and leaders of change

Shared value and new opportunities across business units, better One Merck collaboration



Elimination Program

> **Johannes** Waltz

The Global Health Mandates



Klevesath

Global Health

We improve the health of underserved populations in low- and middle-income countries through Merck's science & technology innovation, and in close collaboration with our external partners.



Merck Global Health Institute

Reinhard-Rupp
Develop transformative health
solutions to support control and
elimination programs related to
infectious disease carrying a major
toll on children.



Johannes Waltz Merck Schisto Elimination Program

Develop a cross-sectoral collaboration among all stakeholders to meet the challenging target of the global elimination of schistosomiasis.



Access to Health

Frédérique Santerre

Improving sustainable access to high-quality health solutions for unserved and underserved populations, regardless of their geographic location or ability to pay.



Our priority areas





Eliminate schistosomiasis as a public health burden



Malaria and infectious diseases product innovation



Creation of new shared value opportunities, including access, health system strengthening and capacity building along the value chain







Eliminate schistosomiasis as a public health burden



Schistosomiasis, the second most devastating tropical disease in terms of public health burden and economic impact.


More than **200 million people** worldwide suffer from schistosomiasis

> 90% of those affected live in sub-Saharan Africa.



Key Facts on Schistosomiasis





The cycle of transmission

- Schistosomiasis is caused by flatworms and is spread through stagnant water.
- The infection rate is especially high among children
- Chronic symptoms that result are learning disabilities, anemia, malnutrition
- It leads to **chronic diseases**, e.g. genital schistosomiasis, bladder cancer





Our goal elimination of schistosomiasis as a public health burden through an integrated approach



2007

Begin of the donation program in partnership with WHO

250 M

Committed annual donation



1 B

PZQ tablets donated

400 M

Treatments of school-aged children enabled

46

African countries supplied





- Innovative tools to control the vector
- Water & sanitation control methods



Treatment

- Next generation of compounds (drug discovery)
- New Ped PZQ formulation for preschoolers
- PZQ optimized formulation
- PZQ use for Female Genital Schistosomiasis







Diagnostics



- Sensitive and specific diagnostics
 - New biomarkers to develop complementary diagnostics

Health System Strengthening



- Initiative for higher education for local researchers
 - Capacity building: from infrastructures to operational research







VISION:

Reduce the global disease burden of schistosomiasis

MISSION:

Develop, register and provide access to a suitable **pediatric praziquantel formulation** to treat schistosomiasis in preschoolers, including infants and toddlers

www.pediatricpraziguantelconsortium.org/





Enhancing knowledge

Through a health education project in Ethiopia with the NALA Foundation, which develops impactful tools to promote changes in hygiene behavior.

Through a number of research programs with local academia and institutions which aim at fostering expertise and know-how in developing countries.





#MakingSchistory

Merck Global Health at the heart of a large community of partners.

2007: **World Health Organization (WHO)** – our strong partner in the fight against schistosomiasis.

2012: **Pediatric Praziquantel Consortium** – today formed by 8 partners and 2 main funders.

2014: Global Schistosomiasis Alliance (GSA) as a key convening platform for the global schistosomiasis community.

The goal: move towards **global elimination** of this insidious disease.

